.
Carers Victoria knows that the mental health and well-being of carers of people with a mental illness are poor. Being able to gather evidence on the effect of hospital admissions on carer and caring family well-being would be significantly useful. Such data would improve understandings of how carer concerns change, reduce or increase over time and at different stages, for example, when the person they support is admitted, treated or discharged from hospital. This could inform the targeting of carer supports.
Carer distress can be caused by a range of factors which would need clarification if it contributed to a consumer's admission. Carers may fear self-harm or suicide by a person they support or harm to a family member by the person. Alternatively, distress may be caused by significant care responsibilities over a sustained period. Support may also be provided by a carer to more than one person and subsequent distress can then be cumulative. Therefore, gathering evidence on the impact to carers from acute bed shortages for people experiencing severe mental illness should consider carer well-being data, based on a range of carer concerns.
It is also important to consider care planning and advance planning undertaken by caring families. Strategies to identify illness onset, and minimise harm, which are mutually agreed to by families and consumers (and supported by the work of other community mental health practitioners and service providers) can be compromised in the long term by a lack of acute bed access. When working well, care relationships support consumer independence. If people in a care relationship have negotiated issues of emergency planning, and a consumer has made choices and decisions, to access particular supports at particular times with the assistance of their carer, then it is important that our hospital system honours those choices.
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To the Editor
Lee and Kulkarni (2017) are right to highlight the paradoxes and interpersonal challenges in managing persons with borderline personality disorder (BPD), and we echo their call for a sensitive approach to this patient group. We wonder, however, if their assumptions about the aetiological role of trauma obscure the complex interplay of other psychological and sociocultural determinants, and risk confusing compassion with collusion.
The role of childhood trauma in BPD is important but should not be overstated. Exposure to trauma is not a sufficient condition for the development of BPD, and childhood trauma does not consistently lead to BPD (Paris, 2014). Genetic predisposition, temperament, chaotic families and the iatrogenic harms of unnecessary psychiatric hospitalisation can all contribute to the manifestation of the disorder in a given individual.
The increasing prevalence of BPD in the developed world (and the recent appearance of the disorder elsewhere) might reflect subtle environmental influences at a population level. For example, deliberate self harm (DSH) could be conceptualised as a cultural meme susceptible to the contagion effects of social media. The simultaneous dissolution of what Millon (1987) termed 'reparative and cohering social customs' can intensify the existing identity confusion of adolescence.
Both DSH and suicide attempts may serve psychodynamic goals beyond either maladaptive help seeking or the inward direction of emotional pain. Ostensibly internalising acts can provide the patient a clinical context for adopting the role of aggressor, resulting in the projection of anger into caregivers. It is for this reason that negative countertransference reactions may be both an entirely normal response to the borderline patient in crisis and a helpful diagnostic 'canary in the coalmine'. It is the clinician response to the countertransference and not the experience itself which is modifiable.
Unfortunately, patients with BPD are prone to perceiving therapeutic limitsetting and reasonable behavioural consequences as being invalidating or punitive. Decision-making capacity and hence moral responsibility are generally preserved in BPD. Effective treatments, such as dialectical behaviour therapy (DBT), are those that promote accountability and steer the person away from the siren song of victimhood. As the individual develops greater control of their emotions and behaviours, they are less likely to generate stigmatising attitudes from others and are more disposed to creating virtuous cycles of interpersonal effectiveness. These principles sit comfortably within the goals of the recovery model and should inform our practice.
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To the Editor
The recent letter (Chopra, 2017) correctly points out that legalisation of 'medical marijuana' is incompatible with good mental health promotion. The views are supported by a recent survey of use in the United States, where the drug is legalised (Hasin et al., 2017) . It notes the concerning trend, that in states where marijuana is legal, illicit use and cannabis use disorders have increased more than in states where the drug is not legal. A prudent course of action would seem to argue for retention of existing prohibitive laws despite widespread use. Use in those with mental health disorders needs to be discouraged, as does heavy use in adolescents, due to an association with potential ongoing neurocognitive impairments.
The statement (Chopra, 2017 ) that the use of medical cannabinoids for any purpose, including research under closely observed conditions ignores known cannabinoid pharmacology and potential therapeutic value. Cannabis sativa and related species contain at least 60 different cannabinoids (Borgelt et al., 2013) . The two principal neuroactive compounds are Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) (Devinsky et al., 2014) . The basis of the plant's psychoactive effects have been aided by the identification of central cannabinoid receptors, and the endogenous cannabinoids, anandamide and 2-arachidonoylglycerol (2-AG) (Borgelt et al., 2013) . Localisation of CB1 receptors to neurons in various brain regions probably explains the physiological and cognitive effects observed with THC. CB2 receptors are located on immune cells, tissues and microglia. Binding to these receptors may explain antiinflammatory and immunosuppressive effects. While THC binds to CB1 and CB2 receptors, CBD is inactive, which likely accounts for its lack of psychoactive properties. Nevertheless, the compound possesses affinity for a wide range of other receptors (Devinsky et al., 2014) . It is these properties which make the compound of interest for therapeutic use in a diverse range of disorders. While epilepsy is perhaps the better characterised use of the compound (Devinsky et al., 2014) , other conditions may potentially benefit from the use of CBD. Therapeutic benefits are not well established however and require placebo controlled trials examining dose response relationships and longterm safety data.
It can be agreed that administering CBD as part of a cocktail derived from 'kitchen sink' extracts of cannabis exhibits poor-quality control over doses administered. Furthermore, the THC content is also likely to vary and confound the interpretation of any outcome. Anecdotal reports of efficacy for intractable epilepsies in children demands a more serious scientific approach.
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